Marshall Wace North America’s Sarepta Therapeutics SRPT Stock Holding History

Marshall Wace North America’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$33.2M	Sell	359,481 -148,823	-29%	-$11.5M	0.14%	162
2021 Q2	$39.5M	Buy	508,304 +92,154	+22%	+$6.99M	0.16%	134
2021 Q1	$31M	Buy	416,150 +406,756	+4,330%	+$37.5M	0.13%	184
2020 Q4	$1.6M	Buy	+9,394	New	+$1.39M	0.01%	814
2020 Q3	–	Sell	-8,048	Closed	-$1.29M	–	1456
2020 Q2	$1.29M	Buy	+8,048	New	+$1.1M	0.01%	695
2020 Q1	–	Sell	-56,904	Closed	-$7.34M	–	1576
2019 Q4	$7.34M	Buy	56,904 +54,363	+2,139%	+$5.49M	0.04%	333
2019 Q3	$192K	Sell	2,541 -22,226	-90%	-$2.62M	﹤0.01%	965
2019 Q2	$3.76M	Sell	24,767 -197,893	-89%	-$24.1M	0.02%	421
2019 Q1	$26.5M	Buy	222,660 +50,038	+29%	+$6.43M	0.19%	118
2018 Q4	$18.8M	Buy	172,622 +15,883	+10%	+$1.99M	0.18%	108
2018 Q3	$25.3M	Sell	156,739 -123,102	-44%	-$16.8M	0.17%	127
2018 Q2	$37M	Sell	279,841 -86,392	-24%	-$8.15M	0.21%	119
2018 Q1	$27.1M	Buy	366,233 +121,512	+50%	+$8.1M	0.14%	171
2017 Q4	$13.6M	Sell	244,721 -133,626	-35%	-$7.08M	0.08%	309
2017 Q3	$17M	Buy	378,347 +365,136	+2,764%	+$14.6M	0.11%	246
2017 Q2	$449K	Buy	+13,211	New	+$430K	﹤0.01%	1104

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's SRPT Position: Q3 2021 in Review

Marshall Wace North America reduced its Sarepta Therapeutics (SRPT) stake by 29% in Q3 2021, selling an estimated $11.5M and leaving 359,481 shares worth $33.2M. The position accounts for 0.14% of the portfolio, ranked #162.

Marshall Wace North America first reported a position in SRPT in Q2 2017 and has held it in 16 quarters since. The position peaked at $39.5M in Q2 2021. 307 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

Marshall Wace North America held 359,481 shares of Sarepta Therapeutics worth $33.2M as of Q3 2021.
Marshall Wace North America sold 148,823 Sarepta Therapeutics shares in Q3 2021, an estimated $11.5M.
Sarepta Therapeutics made up 0.14% of Marshall Wace North America's portfolio in Q3 2021, its #162 holding.
Marshall Wace North America first reported a position in Sarepta Therapeutics in Q2 2017 and has held it in 16 quarters since.
Marshall Wace North America's Sarepta Therapeutics position peaked at $39.5M in Q2 2021.
307 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.